ArticleScientific reports2022
The impact of the ST131 clone on recurrent ESBL-producing E. coli urinary tract infection: a prospective comparative study.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Diversity and Antimicrobial Resistance Profiles of ESBL-ProducingPathogens (Basel, Switzerland) · 2026Article
- Genomic analysis of the virulome and resistome of high-riskJAC-antimicrobial resistance · 2026Article
- Genomic islands and plasmid borne antimicrobial resistance genes drive the evolution of high-risk, ST-131 uropathogenic E. coli NS30.BMC genomics · 2025Article
- High prevalence of MDR and XDR Escherichia coli in hospital wastewater from Shiraz, Iran: ESBL and carbapenemase production.BMC microbiology · 2025Article
- Emergence ofMicrobiology spectrum · 2025Article
- Prevalence and economic evaluation of acute uncomplicated cystitis in women from Japan: a retrospective cohort study.JAC-antimicrobial resistance · 2025Article
- Virulence factors and outcomes in bacteremia caused by extended-spectrum β-lactamase-producing uropathogenic Escherichia coli ST131-H30Rx in a Swedish county.BMC infectious diseases · 2025Article
- Risk Factors and Clinical Impact of Extended-Spectrum Beta-Lactamase (ESBL)-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Assessment of Antimicrobial Resistance and Virulence of Biofilm-Forming UropathogenicAntibiotics (Basel, Switzerland) · 2025Article
- A First Report on Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Genomic epidemiology of extended-spectrum beta-lactamase-producingMicrobial genomics · 2025Article
- Fluoroquinolone resistance in ESKAPE pathogens: evolutionary pathways, one health transmission, and clinical surveillance.Frontiers in microbiology · 2025Review
- Analysis of molecular mechanisms of delafloxacin resistance in Escherichia coli.Scientific reports · 2024Article
- Molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli isolated from lower respiratory tract samples between 2002 and 2019 in the Central Slovenia region.Annals of clinical microbiology and antimicrobials · 2024Article
- Spatial clusters of extended-spectrum beta-lactamase-producing Escherichia coli causing community-onset bacteriuria due to repeat infections: cluster analysis from a large urban medical center, San Francisco, 2014-2020.Antimicrobial resistance and infection control · 2023Article
- High Emergence of Multidrug-Resistant Sequence Type 131 Subclade C2 among Extended-Spectrum β-Lactamase (ESBL)-ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Comparative Genomic Analysis of ST131 Subclade C2 of ESBL-ProducingMicroorganisms · 2023Article
- Genomic Characterization of UropathogenicInternational journal of molecular sciences · 2023Article
- Genome profiling of uropathogenic E. coli from strictly defined community-acquired UTI in paediatric patients: a multicentric study.Antimicrobial resistance and infection control · 2023Article
- Characterization of host and escherichia coli strains causing recurrent urinary tract infections based on molecular typing.BMC microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global emergence of extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-E. coli), mainly causing urinary tract infections (UTI), is of great concern. Almost one third of patients with UTI, develop recurrent UTI (RUTI). We followed 297 patients for one year after their first episode of UTI due to ESBL-E. coli. Our aim was to evaluate the impact of the globally dominant sequence type (ST)131 clone and its clades, on the risk of subsequent recurrences with ESBL-E. coli. Isolates from patients developing RUTI (68/297) were compared with those from patients with sporadic UTI (SUTI, 229/297). No association was found between RUTI and the two most prevalent phylogroups B2 and D, bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.